Iovance Historical Financial Ratios
| IOVA Stock | USD 3.56 0.07 1.93% |
Iovance Biotherapeutics is lately reporting on over 108 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 2.87 or Days Sales Outstanding of 80.25 will help investors to properly organize and evaluate Iovance Biotherapeutics financial condition quickly.
Iovance |
About Iovance Financial Ratios Analysis
Iovance BiotherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Iovance Biotherapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Iovance financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Iovance Biotherapeutics history.
Iovance Biotherapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Iovance Biotherapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Iovance Biotherapeutics sales, a figure that is much harder to manipulate than other Iovance Biotherapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Iovance Biotherapeutics dividend as a percentage of Iovance Biotherapeutics stock price. Iovance Biotherapeutics dividend yield is a measure of Iovance Biotherapeutics stock productivity, which can be interpreted as interest rate earned on an Iovance Biotherapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Most ratios from Iovance Biotherapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Iovance Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.At present, Iovance Biotherapeutics' Book Value Per Share is projected to increase based on the last few years of reporting. The current year's Average Payables is expected to grow to about 31.8 M, whereas PTB Ratio is forecasted to decline to 2.87.
| 2010 | 2024 | 2025 (projected) | Dividend Yield | 0.13 | 0.12 | 0.1 | Price To Sales Ratio | 1.6K | 13.07 | 12.42 |
Iovance Biotherapeutics fundamentals Correlations
Click cells to compare fundamentals
Iovance Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Iovance Biotherapeutics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 9.77 | 4.71 | 2.04 | 3.27 | 3.02 | 2.87 | |
| Book Value Per Share | 4.75 | 4.05 | 3.14 | 2.49 | 2.45 | 2.57 | |
| Free Cash Flow Yield | (0.0393) | (0.0907) | (0.31) | (0.2) | (0.17) | (0.18) | |
| Operating Cash Flow Per Share | (1.28) | (1.48) | (1.49) | (1.84) | (1.54) | (1.22) | |
| Capex To Depreciation | 41.04 | 2.69 | 0.97 | 0.67 | 0.35 | 0.33 | |
| Pb Ratio | 9.77 | 4.71 | 2.04 | 3.27 | 3.02 | 2.87 | |
| Free Cash Flow Per Share | (1.82) | (1.73) | (1.97) | (1.63) | (1.26) | (1.32) | |
| Roic | (0.36) | (0.47) | (0.95) | (0.67) | (0.49) | (0.51) | |
| Net Income Per Share | (1.86) | (2.14) | (2.45) | (1.89) | (1.28) | (1.35) | |
| Payables Turnover | 0.64 | 0.51 | 0.79 | 0.32 | 4.51 | 4.28 | |
| Cash Per Share | 4.55 | 3.29 | 2.96 | 1.19 | 1.12 | 1.88 | |
| Pocfratio | (31.28) | (12.85) | (3.48) | (5.28) | (6.08) | (6.38) | |
| Capex To Operating Cash Flow | (0.23) | (0.16) | (0.0698) | (0.0616) | (0.0314) | (0.0329) | |
| Pfcf Ratio | (25.47) | (11.03) | (3.25) | (4.98) | (5.89) | (6.19) | |
| Days Payables Outstanding | 566.14 | 714.78 | 459.43 | 1.1K | 80.98 | 76.93 | |
| Income Quality | 0.79 | 0.67 | 0.74 | 0.81 | 0.95 | 0.55 | |
| Roe | (0.39) | (0.53) | (0.78) | (0.76) | (0.52) | (0.55) | |
| Ev To Operating Cash Flow | (31.21) | (12.82) | (2.97) | (5.18) | (5.91) | (6.21) | |
| Pe Ratio | (24.95) | (8.93) | (2.61) | (4.31) | (5.76) | (6.05) | |
| Ev To Free Cash Flow | (25.41) | (11.0) | (2.78) | (4.88) | (5.73) | (6.02) | |
| Earnings Yield | (0.0544) | (0.0401) | (0.11) | (0.38) | (0.23) | (0.17) | |
| Net Debt To E B I T D A | 0.0625 | 0.0204 | 0.39 | 0.0913 | 0.15 | 0.14 | |
| Current Ratio | 11.59 | 5.69 | 5.16 | 2.79 | 3.74 | 3.55 | |
| Tangible Book Value Per Share | 4.75 | 4.05 | 3.14 | 1.51 | 1.48 | 1.55 | |
| Shareholders Equity Per Share | 4.75 | 4.05 | 3.14 | 2.49 | 2.45 | 2.57 | |
| Debt To Equity | 0.0787 | 0.12 | 0.17 | 0.13 | 0.0806 | 0.0846 | |
| Capex Per Share | 0.34 | 0.24 | 0.13 | 0.0948 | 0.0382 | 0.0669 | |
| Graham Net Net | 3.74 | 2.27 | 1.93 | 0.38 | 0.7 | 0.73 | |
| Interest Debt Per Share | 0.37 | 0.47 | 0.55 | 0.32 | 0.2 | 0.19 | |
| Debt To Assets | 0.0672 | 0.092 | 0.13 | 0.0972 | 0.0629 | 0.0597 | |
| Enterprise Value Over E B I T D A | (25.52) | (8.9) | (2.32) | (4.38) | (5.28) | (5.54) | |
| Short Term Coverage Ratios | (32.64) | (45.07) | (23.26) | (27.37) | (31.48) | (33.05) | |
| Price Earnings Ratio | (24.95) | (8.93) | (2.61) | (4.31) | (5.76) | (6.05) | |
| Price Book Value Ratio | 9.77 | 4.71 | 2.04 | 3.27 | 3.02 | 2.87 | |
| Price Earnings To Growth Ratio | (1.04) | (0.59) | (0.18) | 0.19 | 0.18 | 0.17 | |
| Days Of Payables Outstanding | 566.14 | 714.78 | 459.43 | 1.1K | 80.98 | 76.93 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 151.892 | Return On Assets | Return On Equity |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.